The inhibition of granulocyte phagocytosis by various components of nasal drops.
The effect of two decongestive substances and two preservatives used in nasal drops on phagocytosis by human granulocytes was studied. The vasoactive substances oxymetazoline chloride and zylometazoline chloride incubated with human granulocytes during 20 min. gave a reduction of phagocytosis to almost zero when using concentrations found in commercially used nasal drops (500 mg/l respectively 1000 mg/l). However, a dilution of 1:100 was consistent with an almost normal phagocytic function. The preservatives benzalkonium chloride and thiomersal gave a dose related reduction of phagocytosis down to zero. A dilution of 1:100 of the benzalkonium chloride solution used commercially (200 mg/l) and a dilution of 1:10 of the thiomersal solution used commercially (24 mg/l) were needed to get an almost normal phagocytic function. These results together with previous studies indicate that the addition of preservatives in nasal drops should be questioned, excluded or replaced with other less harmful substances.
Håkansson
B
B
Department of Otorhinolaryngology, University of Lund, Malmö General Hospital, Sweden.
Linder
C
C
Ohlsson
K
K
Tegner
H
H
Toremalm
N G
NG
D000281:Administration, Intranasal; D001548:Benzalkonium Compounds / Q000494:pharmacology; D006098:Granulocytes / Q000276:immunology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D014663:Nasal Decongestants / Q000494:pharmacology*; D009297:Nasal Mucosa / Q000502:physiology; D010109:Oxymetazoline / Q000494:pharmacology; D010587:Phagocytosis / Q000187:drug effects*; D010592:Pharmaceutic Aids / Q000494:pharmacology*; D011310:Preservatives, Pharmaceutical / Q000494:pharmacology*; D013849:Thimerosal / Q000494:pharmacology
D001548:Benzalkonium Compounds; D007093:Imidazoles; D014663:Nasal Decongestants; D010592:Pharmaceutic Aids; D011310:Preservatives, Pharmaceutical; D013849:Thimerosal; D010109:Oxymetazoline; C009695:xylometazoline